NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Sanofi, one of the world’s top pharmaceutical companies, has increased its adoption of the Medidata Clinical Cloud™ as part of a company-wide initiative to achieve cutting-edge productivity across its global R&D organization. Sanofi, a Medidata enterprise client, will now leverage Medidata’s best-in-class technology for risk-based monitoring of clinical trial sites, in addition to the broad set of solutions and analytics already used through the Medidata platform to improve operational efficiencies, resource savings and decision making.
As a founding member of TransCelerate BioPharma Inc. —a non-profit organization dedicated to improving the health of people worldwide by accelerating and simplifying the R&D of innovative new therapies through industry collaboration—Sanofi is engaged in developing an industry-wide approach for targeted monitoring of clinical trial sites to enhance productivity while protecting patient safety and data quality. The company has conducted risk-based monitoring for the past several years and selected Medidata’s targeted source document verification (Medidata Rave® TSDV) capability to provide an efficient, scalable and auditable technology solution for its clinical operations and data management teams.
“We’re proud that Medidata’s cloud-based platform is supporting Sanofi in driving the effective and high-quality delivery of new medicines to patients worldwide,” said Glen de Vries, president of Medidata. “Sanofi is an early adopter of risk-based monitoring practices and has been quick to implement TransCelerate’s recommendations on this important methodology, streamlining the way clinical trials are conducted and monitored around the world.”
In 2012, Sanofi adopted Medidata’s cloud-based technology for electronic data capture and management (EDC), safety data collection, medical coding, clinical business analytics and industry benchmarks. The addition of Rave TSDV—the solution unified with Medidata’s technology platform to support risk-based monitoring—provides Sanofi’s research teams with flexible tools that reduce timelines, increase productivity and provide quick access to meaningful data.
“Today, more than 30 percent of a clinical trial budget can be required to cover site monitoring costs,” de Vries added. “By supporting the implementation of a risk-based approach to site monitoring that more effectively targets identifiable risks, Medidata's platform can help reduce the resource requirements for sponsors, CROs, and the doctors and nurses collaborating on a study, without compromising the quality or data integrity, and ultimately streamlining how life-enhancing treatments get into the hands of patients.”
Connect with Medidata:
- Read our blog, Geeks Talk Clinical
- Tweet this: @Sanofi expands use of @Medidata technology to streamline operations & advance cutting-edge clinical development http://bit.ly/QFmCp1
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About Medidata Solutions
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global clients, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.
